La vendita allo scoperto per Henry Schein dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Henry Schein. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Henry Schein (NASDAQ:HSIC) Azioni, Report sulle vendite allo scoperto

Henry Schein

Henry Schein Inc is a solutions company for healthcare professionals powered by a network of people and technology. The company is a provider of healthcare products and services primarily to office-based dental and medical practitioners, as well as alternate sites of care. The company operates in two reportable segments; health care distribution and technology & value-added services. The healthcare distribution segment is engaged in combining global dental and medical businesses and distributes consumable products, small equipment, laboratory products, and Vitamins. The technology and value-added services reportable segment provides software, technology & other value-added services to health care practitioners. The majority of revenue is derived from the health care distribution segment.

Henry Schein Inc

Henry Schein's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NYSE">HSIC</a>) short percent of float has risen 5.56% since its last report. The company recently reported that it has 6.80 million shares sold short, which is 6.08% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Henry Schein Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732111228_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Henry Schein has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Henry Schein's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Henry Schein's peer group average for short interest as a percentage of float is 5.46%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

HSIC

Peering Into Henry Schein's Recent Short Interest

Henry Schein Signed An Agreement To Acquire Acentus, A National Medical Supplier Specializing In The Delivery Of Continuous Glucose Monitors (cgms), For An Undisclosed Amount

WIIM

Henry Schein shares are trading higher. The stock may be moving higher after activist investor Ananym Capital announced plans for the company and began pushing for changes.

News

Management

Activist Investor Ananym Capital Pushes For Changes At Henry Schein; Ananym Wants Refreshed Board, CEO Succession Plan, Review Of Alternatives For Medical Distribution Business; Ananym Argues Changes Could Push Up Share Price, Earnings

Analysts' ratings for Henry Schein (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $79.5, a high estimate of $82.00, and a low estimate of $74.00. Observing a downward trend, the current average is 1.24% lower than the prior average price target of $80.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1730926842_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Henry Schein among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$82.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Ross Muken</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$74.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$82.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Rachel Vatnsdal</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$88.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Henry Schein. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Henry Schein compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of Henry Schein's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/HSIC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Henry Schein analyst ratings.</a>
<h2>Get to Know Henry Schein Better</h2>
Henry Schein Inc is a solutions company for healthcare professionals powered by a network of people and technology. The company is a provider of healthcare products and services primarily to office-based dental and medical practitioners, as well as alternate sites of care. The company operates in two reportable segments; health care distribution and technology &amp; value-added services. The healthcare distribution segment is engaged in combining global dental and medical businesses and distributes consumable products, small equipment, laboratory products, and Vitamins. The technology and value-added services reportable segment provides software, technology &amp; other value-added services to health care practitioners. The majority of revenue is derived from the health care distribution segment.
<h3>Key Indicators: Henry Schein's Financial Health</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Henry Schein's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 1.16%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Henry Schein's net margin is impressive, surpassing industry averages. With a net margin of 3.32%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Henry Schein's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 2.92%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Henry Schein's ROA stands out, surpassing industry averages. With an impressive ROA of 1.02%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Henry Schein's debt-to-equity ratio is below the industry average. With a ratio of 0.81, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Analyst Ratings For Henry Schein

Barrington Research analyst Michael Petusky maintains Henry Schein (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) with a Outperform and maintains $82 price target.

Price Target

Barrington Research Maintains Outperform on Henry Schein, Maintains $82 Price Target

On Tuesday,&nbsp;Henry Schein Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) reported a third-quarter adjusted EPS of $1.22, down 7.6% year-over-year,&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">beating the consensus of $1.17</a>.
Sales were $3.17 billion, an increase of 0.4%, missing&nbsp;the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41739359/henry-schein-reports-third-quarter-2024-financial-results-and-increases-2024-financial-guidance" rel="noreferrer noopener">consensus of $3.24 billion</a>.
Sales growth reflects 3.2% growth from acquisitions, a 0.2% decrease resulting from foreign currency exchange rates, a 0.4% decrease from lower sales of personal protective equipment (PPE), primarily due to lower glove pricing, and the pace of recovery from the cyber incident late last year.
Internal sales decreased by 2.6%, including a 0.4% decrease from lower PPE sales.
Global dental segment sales were $1.9 billion, down 1.6%, and medical segment sales increased by 2.9% (down 4.8% internally) to $1.1 billion.
Technology and Value-Added Services sales increased 5.1% (internal decline of 1.1%) to&nbsp;$0.2 billion.
"We believe we continued to steadily gain market share in our dental and medical distribution businesses following last year's cyber incident. Our dental equipment business is showing ongoing stability in&nbsp;North America&nbsp;and increased investment by customers in&nbsp;Europe,&nbsp;Australia and New Zealand. Implant and endodontic products had good growth in&nbsp;Europe&nbsp;and&nbsp;Brazil, as well as&nbsp;North America&nbsp;following the successful launch of the BioHorizons Tapered Pro Conical implant in the U.S.,"&nbsp;said&nbsp;Stanley Bergman, Chairman of the Board and CEO.
Restructuring Plan:&nbsp;During the third quarter of 2024, the company recorded&nbsp;$48 million&nbsp;in restructuring costs. Actions approved in the third quarter under the new restructuring plan are estimated to provide over&nbsp;$50 million&nbsp;in annual run-rate savings.
The company expects $75 million&nbsp;to&nbsp;$100 million&nbsp;in annual run-rate savings by the end of 2025.
Guidance: "Acquisitions made during our 2022 to 2024 strategic planning cycle, along with new product launches, are delivering strong financial results, and our restructuring plan is on target. We also continue to return capital to shareholders through our share repurchase program. As a result, we exceeded our financial expectations for the quarter, and so today we are increasing our non-GAAP EPS guidance," Bergman concluded.
Henry Schein expects 2024 sales growth of approximately 4%-5% over 2023, compared with&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38679316/dental-supplies-distributor-henry-scheins-tech-segment-provides-some-stability-in-c" rel="noreferrer noopener">prior guidance of </a>4% – 6% <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38679316/dental-supplies-distributor-henry-scheins-tech-segment-provides-some-stability-in-c" rel="noreferrer noopener">growth</a>.
The company expects 2024 adjusted EPS of $4.74-$4.82 compared with prior guidance of $4.70-$4.82 and a consensus of $4.75.
Price Action: At last check on Tuesday, HSIC stock was down 4.60% at $69.01.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/11/41741814/walgreens-agrees-to-100-million-settlement-over-alleged-deceptive-pricing-of-generic-drugs" target="_blank" rel="noreferrer noopener">Walgreens Agrees To $100 Million Settlement Over Alleged Deceptive Pricing Of Generic Drugs</a></li>
</ul>
Photo by Casimiro PT via Shutterstock

Earnings

Guidance

Health Care

Movers

General

Henry Schein Q3 Earnings: Sees Recovery From Cyber Incident, Says Dental Equipment Business Shows Stability In North America

2024 Financial Guidance
<ul>
<li>2024 total sales growth is now expected to be 4% to 5% over 2023, compared with prior guidance of 4% to 6% growth.</li>
<li>2024 non-GAAP diluted EPS attributable to Henry Schein, Inc. is now expected to be $4.74 to $4.82, compared with prior guidance of $4.70 to $4.82, and reflects growth of 5% to 7% compared with 2023 non-GAAP diluted EPS of $4.50.</li>
<li>2024 Adjusted EBITDA is expected to grow in the low-double-digit percentages versus 2023 Adjusted EBITDA, and is unchanged compared to prior guidance.</li>
</ul>

Henry Schein Expects 2024 Adjusted EPS Of $4.74 To $4.82 Compared With Prior Guidance Of $4.70-$4.82 And Consensus Of $4.75

Henry Schein (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) reported quarterly earnings of $1.22 per share which beat the analyst consensus estimate of $1.17 by 4.27 percent. The company reported quarterly sales of $3.17 billion which missed the analyst consensus estimate of $3.24 billion by 1.90 percent. This is a 0.38 percent increase over sales of $3.16 billion the same period last year.

Henry Schein Q3 2024 Adj EPS $1.22 Beats $1.17 Estimate, Sales $3.17B Miss $3.24B Estimate

During the last three months, 8 analysts shared their evaluations of Henry Schein (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>), revealing diverse outlooks from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Henry Schein, presenting an average target of $79.25, a high estimate of $92.00, and a low estimate of $70.00. Experiencing a 2.76% decline, the current average is now lower than the previous average price target of $81.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1728410409_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Henry Schein among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ross Muken</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$74.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$82.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Rachel Vatnsdal</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$72.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$82.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Ross Muken</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$70.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$82.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$92.00</td>
<td>$81.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Henry Schein. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Henry Schein compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Henry Schein's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Henry Schein's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/HSIC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Henry Schein analyst ratings.</a>
<h2>All You Need to Know About Henry Schein</h2>
Henry Schein Inc is a solutions company for healthcare professionals powered by a network of people and technology. The company is a provider of healthcare products and services primarily to office-based dental and medical practitioners, as well as alternate sites of care. The company operates in two reportable segments; health care distribution and technology &amp; value-added services. The healthcare distribution segment is engaged in combining global dental and medical businesses and distributes consumable products, small equipment, laboratory products, and Vitamins. The technology and value-added services reportable segment provides software, technology &amp; other value-added services to health care practitioners. The majority of revenue is derived from the health care distribution segment.
<h3>A Deep Dive into Henry Schein's Financials</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Henry Schein's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 1.16%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Henry Schein's net margin excels beyond industry benchmarks, reaching 3.32%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Henry Schein's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 2.92%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Henry Schein's ROA excels beyond industry benchmarks, reaching 1.02%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.81.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Henry Schein Stands With Analysts

Evercore ISI Group analyst Ross Muken maintains Henry Schein (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) with a In-Line and raises the price target from $70 to $74.

Evercore ISI Group Maintains In-Line on Henry Schein, Raises Price Target to $74

Henry Schein Reaches Agreement With Swiss Company vVARDIS To Serve As Exclusive Distributor Of Drill-free Curodont Repair Fluoride Plus Product To Dental Service Organizations In US

On September 9, a recent SEC filing unveiled that Lorelei McGlynn, SVP at Henry Schein (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) made an insider sell.
What Happened: McGlynn's recent Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001000228/000095017024104816//Archives/edgar/data/1000228/000095017024104816/0000950170-24-104816-index.htm">U.S. Securities and Exchange Commission</a> on Monday unveiled the sale of 21,035 shares of Henry Schein. The total transaction value is $1,457,725.
Monitoring the market, Henry Schein's shares down by 0.0% at $68.89 during Tuesday's morning.
<h3>Discovering Henry Schein: A Closer Look</h3>
Henry Schein Inc is a solutions company for healthcare professionals powered by a network of people and technology. The company is a provider of healthcare products and services primarily to office-based dental and medical practitioners, as well as alternate sites of care. The company operates in two reportable segments; health care distribution and technology &amp; value-added services. The healthcare distribution segment is engaged in combining global dental and medical businesses and distributes consumable products, small equipment, laboratory products, and Vitamins. The technology and value-added services reportable segment provides software, technology &amp; other value-added services to health care practitioners. The majority of revenue is derived from the health care distribution segment.
<h3>Breaking Down Henry Schein's Financial Performance</h3>
Revenue Growth: Henry Schein's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 1.16%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Key Profitability Indicators:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 32.46%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): With an EPS below industry norms, Henry Schein exhibits below-average bottom-line performance with a current EPS of 0.81.
</li>
</ul>
Debt Management: Henry Schein's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.81.
Navigating Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 25.42, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 0.72 is above industry norms, reflecting an elevated valuation for Henry Schein's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio 13.41 is above the industry average, suggesting that the market values the company more highly for each unit of EBITDA. This could be attributed to factors such as strong growth prospects or superior operational efficiency.
</li>
</ul>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Exploring the Significance of Insider Trading</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>Breaking Down the Significance of Transaction Codes</h3>
When dissecting transactions, the focal point for <a href="https://www.benzinga.com/money/investing-tools">investors</a> is often those occurring in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001000228">Check Out The Full List Of Henry Schein's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Sell Alert: Lorelei McGlynn Cashes Out $1.46M In Henry Schein Stock

Mark E Mlotek, EVP at Henry Schein (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>), reported an insider sell on August 15, according to a new SEC filing. 
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001000228/000095017024097634//Archives/edgar/data/1000228/000095017024097634/0000950170-24-097634-index.htm">U.S. Securities and Exchange Commission</a> on Thursday showed that Mlotek sold 3,000 shares of Henry Schein. The total transaction amounted to $207,360. 
The latest update on Friday morning shows Henry Schein shares down by 0.0%, trading at $69.78.
<h3>Unveiling the Story Behind Henry Schein</h3>
Henry Schein Inc is a solutions company for healthcare professionals powered by a network of people and technology. The company is a provider of healthcare products and services primarily to office-based dental and medical practitioners, as well as alternate sites of care. The company operates in two reportable segments; health care distribution and technology &amp; value-added services. The healthcare distribution segment is engaged in combining global dental and medical businesses and distributes consumable products, small equipment, laboratory products, and Vitamins. The technology and value-added services reportable segment provides software, technology &amp; other value-added services to health care practitioners. The majority of revenue is derived from the health care distribution segment.
<h3>Henry Schein: A Financial Overview</h3>
Revenue Growth: Henry Schein displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 1.16%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: Achieving a high gross margin of 32.46%, the company performs well in terms of cost management and profitability within its sector.
</li>
<li>
Earnings per Share (EPS): Henry Schein's EPS is below the industry average. The company faced challenges with a current EPS of 0.81. This suggests a potential decline in earnings.
</li>
</ul>
Debt Management: Henry Schein's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.81.
Navigating Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 25.75, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 0.73 as compared to the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Henry Schein's EV/EBITDA ratio, surpassing industry averages at 13.55, positions it with an above-average valuation in the market.
</li>
</ul>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Pay Attention to Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>Exploring Key Transaction Codes</h3>
Surveying the realm of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often give prominence to those unfolding in the open market, systematically detailed in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001000228">Check Out The Full List Of Henry Schein's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Henry Schein EVP Sold $207K In Company Stock

JP Morgan analyst Rachel Vatnsdal maintains Henry Schein (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) with a Overweight and lowers the price target from $88 to $80.

JP Morgan Maintains Overweight on Henry Schein, Lowers Price Target to $80

UBS analyst Kevin Caliendo maintains Henry Schein (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) with a Neutral and lowers the price target from $75 to $72.

UBS Maintains Neutral on Henry Schein, Lowers Price Target to $72

Baird analyst Jeff Johnson maintains Henry Schein (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) with a Outperform and lowers the price target from $92 to $82.

Baird Maintains Outperform on Henry Schein, Lowers Price Target to $82

Evercore ISI Group analyst Ross Muken maintains Henry Schein (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) with a In-Line and lowers the price target from $72 to $70.

Evercore ISI Group Maintains In-Line on Henry Schein, Lowers Price Target to $70

Henry Schein (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Henry Schein, revealing an average target of $84.8, a high estimate of $92.00, and a low estimate of $72.00. This current average has decreased by 0.47% from the previous average price target of $85.20. 
<img src="https://www.benzinga.com/files/images/story/2024/1723039249_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of Henry Schein by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$82.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$92.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Ross Muken</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$72.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$92.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$86.00</td>
<td>$86.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Henry Schein. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Henry Schein compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Henry Schein's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Henry Schein's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/HSIC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Henry Schein analyst ratings.</a>
<h2>Get to Know Henry Schein Better</h2>
Henry Schein Inc is a solutions company for healthcare professionals powered by a network of people and technology. The company is a provider of healthcare products and services primarily to office-based dental and medical practitioners, as well as alternate sites of care. The company operates in two reportable segments; health care distribution and technology &amp; value-added services. The healthcare distribution segment is engaged in combining global dental and medical businesses and distributes consumable products, small equipment, laboratory products, and Vitamins. The technology and value-added services reportable segment provides software, technology &amp; other value-added services to health care practitioners. The majority of revenue is derived from the health care distribution segment.
<h3>Henry Schein: Financial Performance Dissected</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Positive Revenue Trend: Examining Henry Schein's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 3.66% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 2.93%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Henry Schein's ROE excels beyond industry benchmarks, reaching 2.56%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Henry Schein's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.9% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Henry Schein's debt-to-equity ratio is below the industry average at 0.76, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 5 Analyst Projections For Henry Schein

Meeting to be held in London on November 18 hosted by Piper Sandler. Published first on TheFly – the ultimate source for real-time, market-moving b...

Henry Schein management to meet with Piper Sandler

Henry Schein gains amid activist speculation after 13F filing, conference appearance

Henry Schein extends gain on report of activist stake, push for board changes

Activist Ananym Capital Management is urging Henry Schein (HSIC) to refresh its board, cut costs, tackle succession planning and consider selling i...

Ananym urges Henry Schein to cut spending, sell unit, Reuters reports

Piper Sandler analyst Jason Bednar maintained a Buy rating on Henry Schein (HSIC – Research Report) today and set a price target of $83.00. The com...

Piper Sandler Keeps Their Buy Rating on Henry Schein (HSIC)

Henry Schein (HSIC) announced that it has signed an agreement to acquire Acentus, a national medical supplier specializing in the delivery of Conti...

Henry Schein to acquire Acentus, terms not disclosed

Henry Schein to acquire Acentus

Henry Schein: Another Day, Another Purchase

Henry Schein (HSIC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on November 18. Analyst Michael Cherny...

Hold Rating Maintained for Henry Schein Amid Market Challenges and Activist Investor Influence

Tracking Al Gore's Generation Investment Management Portfolio - Q3 2024 Update

AHCO

AMAT

AMZN

CBRE

CLVT

COSM

HTHT

MELI

MSFT

NTNX

PDCO

RELY

SCHW

SOPH

TOST

TRMB

TSMWF

TWLO

TYGO

VEEV

WDAY

Press Releases

Henry Schein Builds Nearly 23,000 Hygiene Kits for Families Staying at Ronald McDonald House Charities Around the World

Henry Schein to Webcast Third Quarter 2024 Conference Call on Tuesday, November 5, 2024 at 10:00 a.m. ET

Supporting Cancer Patients: Henry Schein's Practice Pink Program Raises $2 Million Over 18 Years

Henry Schein Opens Henry Schein Cares Foundation 2024 Relief Fund and Commits Up to $500,000 in Cash and Essential Health Care Supplies to Support the Southeast U.S.

Comments

Henry Schein

Vendite allo scoperto

Henry Schein (NASDAQ:HSIC) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO